{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:37:26Z","timestamp":1771475846816,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Surgery-based multimodality therapies for treatment of malignant pleural mesothelioma have been clinically explored in the past decades. In this regard, hyperthermic intrathoracic or intrapleural chemotherapy has been used as one of the multimodality therapies. The question addressed was In patients with malignant pleural mesothelioma who undergo macroscopic complete resection (MCR) does performing a Hyperthermic intrathoracic chemotherapy (HITOCH) lead to improvement in survival? The trial was registered in PROSPERO <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/\" ext-link-type=\"uri\">https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link> under registration number: CRD42024588823.<\/jats:p>\n          <jats:p>Three hundred five papers were found using the reported search, 21 were relevant to our topic and only 7 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Six studies demonstrated a survival benefit for patients receiving HITOCH with a median survival ranging from 13\u201335\u00a0months in comparison to 11 -22.8\u00a0months for the non HITOCH group. Three out of the five studies compared extra-pleural pneumonectomy (EPP) to extended pleurectomy decortication (EPD) as the surgical preference for MCR. Only one study by Van Sandick et al. found a negative outcome with HITOCH in patients performing EPP (11\u00a0months vs 29\u00a0months). There was no reported mortality in relation to complications associated with HITOCH. The most common complication was atrial fibrillation followed by renal impairment. Despite the heterogeneity, small number of cases and lack of prospective randomised controlled trials, the body of evidence identified in this work demonstrates that HITHOC added to MCR in patients with pleural mesothelioma is safe and feasible. Possible improvement in recurrence free survival and overall survival warrant investigation in a randomised controlled trial.<\/jats:p>","DOI":"10.1186\/s12957-025-03748-8","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:40:51Z","timestamp":1744195251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma after cytoreductive surgical procedures: a systematic review"],"prefix":"10.1186","volume":"23","author":[{"given":"Hany Hasan","family":"Elsayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Elanany Elsaid","family":"Elanany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Tarek","family":"ElSayegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly Sherif","family":"Hassaballa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Abdel-gayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"1","key":"3748_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.athoracsur.2024.02.022","volume":"118","author":"A Nakamura","year":"2024","unstructured":"Nakamura A, Hashimoto M, Kuroda A, Matsumoto S, Kondo N, Kitajima K, Minami T, Kuribayashi K, Kijima T, Hasegawa S. Impact of Operation on Disease Progression and Survival of Patients With Pleural Mesothelioma. Ann Thorac Surg. 2024Jul;118(1):216\u201323.","journal-title":"Ann Thorac Surg"},{"issue":"8","key":"3748_CR2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/cancers16081587","volume":"16","author":"LV Klotz","year":"2024","unstructured":"Klotz LV, Zimmermann J, M\u00fcller K, Kov\u00e1cs J, Hassan M, Koller M, Schmid S, Huppertz G, Markowiak T, Passlick B, Hofmann HS, Winter H, Hatz RA, Eichhorn ME, Ried M. Multimodal Treatment of Pleural Mesothelioma with Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy: Impact of Additive Chemotherapy. Cancers (Basel). 2024Apr 20;16(8):1587.","journal-title":"Cancers (Basel)"},{"key":"3748_CR3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1245\/s10434-008-9899-9","volume":"15","author":"JW Van Sandick","year":"2008","unstructured":"Van Sandick JW, Kappers I, Baas P, Haas RL, Klomp HM. Surgical treatment in the management of malignant pleural mesothelioma: a single institution\u2019s experience. Ann Surg Oncol. 2008;15:1757\u201364.","journal-title":"Ann Surg Oncol"},{"key":"3748_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jtcvs.2009.02.046","volume":"138","author":"TR Tilleman","year":"2009","unstructured":"Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405\u201311.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3748_CR5","doi-asserted-by":"crossref","unstructured":"Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva. MC, Baldini EH, Bueno R, Richards WG. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145:955\u2013963.","DOI":"10.1016\/j.jtcvs.2012.12.037"},{"key":"3748_CR6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.rmed.2013.01.010","volume":"107","author":"AF Isik","year":"2013","unstructured":"Isik AF, Sanli M, Yilmaz M, Meteroglu F, Dikensoy O, Sevinc A, Camci C, Tuncozgur B, Elbeyli L. Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies. Respir Med. 2013;107:762\u20137.","journal-title":"Respir Med"},{"key":"3748_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11748-015-0535-x","volume":"63","author":"H Ishibashi","year":"2015","unstructured":"Ishibashi H, Kobayashi M, Takasaki C, et al. Interim results of pleurectomy\/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy. Gen Thorac Cardiovasc Surg. 2015;63:395\u2013400.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"Suppl 1","key":"3748_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s13193-018-0859-y","volume":"10","author":"MD Patel","year":"2019","unstructured":"Patel MD, Damodaran D, Rangole A, Shaikh S, Shah K, Bagwade R, Bhatt A. Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies-Experience from Indian Centers. Indian J Surg Oncol. 2019Feb;10(Suppl 1):91\u20138.","journal-title":"Indian J Surg Oncol"},{"key":"3748_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-024-01986-1","author":"HH Elsayed","year":"2024","unstructured":"Elsayed HH, Sharkawy HY, Ahmed MA, Abdel-Gayed M, Eldewer M. Effect of intraoperative hyperthermic intrathoracic chemotherapy after pleurectomy decortication for treatment of malignant pleural mesothelioma: a comparative study. Updates Surg. 2024. https:\/\/doi.org\/10.1007\/s13304-024-01986-1.","journal-title":"Updates Surg"},{"key":"3748_CR10","doi-asserted-by":"crossref","unstructured":"Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, Bilancia R, Keni M, Popat S, O'Brien M, Tokaca N, Maskell N, Stadon L, Fennell D, Nelson L, Edwards J, Tenconi S, Socci L, Rintoul RC, Wood K, Stone A, Muthukumar D, Ingle C, Taylor P, Cove-Smith L, Califano R, Summers Y, Tasigiannopoulos Z, Bille A, Shah R, Fuller E, Macnair A, Shamash J, Mansy T, Milton R, Koh P, Ionescu AA, Treece S, Roy A, Middleton G, Kirk A, Harris RA, Ashton K, Warnes B, Bridgeman E, Joyce K, Mills N, Elliott D, Farrar N, Stokes E, Hughes V, Nicholson AG, Rogers CA; MARS 2 Investigators. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457\u2013466.","DOI":"10.2139\/ssrn.4590908"},{"issue":"30","key":"3748_CR11","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.2217\/fon-2021-0317","volume":"17","author":"M Migliore","year":"2021","unstructured":"Migliore M, Combellack T, Williams J, Kornaszewska M, Valtzoglou V, Pirtnieks A. Hyperthermic intrathoracic chemotherapy in thoracic surgical oncology: future challenges of an exciting procedure. Future Oncol. 2021Oct;17(30):3901\u20134.","journal-title":"Future Oncol"},{"key":"3748_CR12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.21037\/atm-20-7247","volume":"9","author":"M Migliore","year":"2021","unstructured":"Migliore M, Ried M, Molins L, Lucchi M, Ambrogi M, Molnar TF, Hofmann H-S. Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma. Ann Transl Med. 2021;9:960.","journal-title":"Ann Transl Med"},{"key":"3748_CR13","doi-asserted-by":"crossref","unstructured":"Migliore M, Fiore M, Filippini T, Tumino R, Sabbioni M, Spatola C, Polosa R, Vigneri P, Nardini M, Castorina S, Basile F, Ferrante M; University of Catania Study Group of Malignant Pleural Mesotelioma. Comparison of video-assisted pleurectomy\/decortication surgery plus hyperthermic intrathoracic chemotherapy with VATS talc pleurodesis for the treatment of malignant pleural mesothelioma: A pilot study. Heliyon. 2023;9(6):e16685.","DOI":"10.1016\/j.heliyon.2023.e16685"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03748-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03748-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:40:55Z","timestamp":1744195255000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03748-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3748"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03748-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}